SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International ...

FibroGen ( (FGEN) ) just unveiled an announcement. On August 18, 2025, FibroGen announced that it received regulatory approval from the China State Administration for Market Regulation for the sale ...

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...

FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic ...

FibroGen Inc (FGEN) reports significant cost reductions and a strengthened cash position, setting the stage for future growth ...

Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now ...

FibroGen plans to file up to two INDs: FG-3165 (1Q 2024) and FG-3163 (4Q 2023). Additionally, the company expects to initiate a Phase 2 trial of FG-3246, targeting metastatic castration-resistant ...

FibroGen is cracking down on former employees accused of trade secret theft. The company filed a lawsuit in the U.S. District Court in the Northern District of California.

The stock price of FibroGen (NASDAQ: FGEN), a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a larger ...

FibroGen tumbled 43% after issuing a clarification on late-stage safety analyses for its anemia drug candidate, roxadustat. The company said it identified "post-hoc changes to the stratification ...